Henlius HLX01 (Rituximab Injection) Wins "Biosimilar Initiative of the Year" at Global Generics & Biosimilars Awards 2019

SHANGHAI, Nov. 7, 2019 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), a leading biopharmaceutical company inChina focusing on oncology and autoimmune diseases, won the award of "Biosimilar Initiative of the Year" (HLX01, rituximab injection) and was also shortlisted for the award of "t...